Odyssey Therapeutics, Inc., a clinical-stage biopharmaceutical company seeking to transform the standard of care for patients suffering from autoimmune and inflammatory diseases by developing medicines that precisely target disease pathology, today announced the closing of a $213 million Series D financing. In addition to participation from all existing investors, new investors included Affinity Asset Advisors, Dimension Capital, Jeito Capital, Lightspeed Ventures, TPG Life Sciences Innovations, and Wedbush Healthcare Partners. Proceeds will support the advancement of Odyssey’s portfolio of clinical and preclinical medicines designed to precisely treat the drivers of complex autoimmune diseases.

“As we advance our programs towards important clinical milestones, we’re focused on translating our scientific efforts into meaningful benefit for patients,” said Gary D. Glick, Ph.D., Founder and CEO of Odyssey Therapeutics. “I’m thankful for the continued support from our investors and their enthusiasm for our mission of delivering truly transformative medicines to patients suffering from inflammatory diseases.”

Read More – Podonos Raises $2.4M in Pre-Seed Funding

In addition to the fundraise, Shelley Chu, M.D., Ph.D., Partner at Lightspeed Ventures, Paulina Hill, Ph.D., Partner at Sanofi Ventures, Nan Li, Founder and Managing Partner at Dimension Capital, Carolyn Ng, Ph.D., Business Unit Partner with TPG Life Sciences Innovations, and Ksenija Pavletic, Partner and CCO at Jeito Capital, will join Odyssey’s Board of Directors.

“This financing is a testament to the important medicines Odyssey is working to discover and deliver to patients,” said Jeff Leiden, M.D., Ph.D., Chairman of the Odyssey Board. “I am delighted to welcome our new investors and work alongside our new board members as Odyssey continues to advance its programs through clinical development.”

Since its founding in 2021, Odyssey has built comprehensive drug discovery and development capabilities. The company has driven an internally discovered program from ideation through multiple clinical milestones, nominated multiple development candidates, and established several collaborations with pharmaceutical leaders and biotech innovators.

Read More – PsiQuantum Raises $1 Billion in Series E Funding